UK-383367
Based on 1 Customer Validation
UK-383367 is an orally available pro-collagen C-protease inhibitor (BMP-1) with an IC50 value of 44 nM. UK-383367 can reduce renal fibrosis and inflammation in chronic kidney disease (CKD) and may be used to study postoperative skin scarring.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 348622-88-8
- Formula: C15H24N4O4
- Molecular Weight:324.38
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
44 nM
Compound: 7, UK-383367
|
Inhibition of human procollagen C-proteinase expressed in CHO cells by fluorescence assay
Inhibition of human procollagen C-proteinase expressed in CHO cells by fluorescence assay
|
[PMID: 18945617] |
| CHO | IC50 |
44 nM
Compound: 1
|
Inhibition of human procollagen C-proteinase expressed in CHO cells
Inhibition of human procollagen C-proteinase expressed in CHO cells
|
[PMID: 17591762] |
| Fibroblast | IC50 |
2100 nM
Compound: 7, UK-383367
|
Reduction in collagen deposition in human fibroblasts after 8 days by HPLC
Reduction in collagen deposition in human fibroblasts after 8 days by HPLC
|
[PMID: 18945617] |
UK-383367 (100-1000 nM, 24 h) inhibits the activity of NRK-49F cells[1].
UK-383367 (100-200 nM, 30 min) effectively suppresses the fibrotic response induced by TGF-β1 in mPTCs cells and shows a direct anti-fibrotic effect on renal cells in NRK-49F cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:mPTCs induced by TGF-β
-
Concentration:0, 100, 200, 300, 400, 800, 1000 nM
-
Incubation Time:24 h
-
Result:Inhibited cell proliferation.
-
Cell Line:mPTCs induced by TGF-β, NRK-49F
-
Concentration:100, 200 nM
-
Incubation Time:30 min
-
Result:Inhibited the induction of collagen I/III, fibronectin, and α-SMA in cells, blocked the activation of NRK-49F cells, and blocked the activation of NRK-49F renal fibroblasts.
Pharmacokinetics of single intravenous and oral administration in rats and dogs[2]
| Animal | Intravenous dose (mg/kg) | Elimination half-life (h) | Plasma clearance (mL/min•kg) | Volume of distribution (1/kg) | Oral dose (mg/kg) | Cmax (ng/mL) | Tmax (h) | Oral bioavailability (%) |
| Male rat | 2.0 | 0.8 | 157 | 12.0 | / | / | / | / |
| Male dog | 0.5 | 1.5 | 35 | 4.6 | 2 | 110 | 0.5-1.5 | 13 |